We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Progression of Undiagnosed Cutaneous T-Cell Lymphoma During Efalizumab Therapy

Claudia Hernandez, MD; Sophie M. Worobec, MD; Sujata S. Gaitonde, MD; Monika L. Kiripolsky, MD; Kristen Aquino, BS
Arch Dermatol. 2009;145(1):92-94. doi:10.1001/archdermatol.2008.530.
Text Size: A A A
Published online


Leonardi  CLToth  DCather  JC  et al.  A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006;213 (3) 204- 214
PubMed Link to Article[[XSLOpenURL/10.1159/000095037]]
 Raptiva [package insert].  South San Francisco, CA: Genentech; 2008
Berthelot  CCather  JMJones  DDuvic  M Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006;6 (4) 329- 332
PubMed Link to Article[[XSLOpenURL/10.3816/CLM.2006.n.008]]
Bommakanti  SPatil  AEshoa  EChitambar  CR Efalizumab-associated lymphoproliferative disease. J Drugs Dermatol 2007;6 (6) 646- 648
Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Tumors developed on the face, ears, chest, and back despite bexarotene therapy. A, Generalized erythema is visible on the chest, face, abdomen, and arms, sparing the body folds; numerous firm erythematous nodules are present on the face. B, Multiple erythematous nodules are scattered on the patient's back.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Efalizumab and progression of undiagnosed follicular mycosis fungoides. Arch Dermatol 2009;145(7):843-4; author reply 844.
Lymphomatoid papulosis while on efalizumab. J Am Acad Dermatol 2009;61(3):540-1.